Article

Trial to study potential MMD treatment

Waltham, MA-OXiGENE Inc. is launching a phase II clinical trial of its lead compound, Combretastatin A4 Prodrug (CA4P), in patients with myopic macular degeneration (MMD) under an investigational new drug application (NDA) submitted to the FDA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
Related Content
FDA approves first biosimilar product for retinal diseases
November 1st 2021

Making the grade: FDA approves first biosimilar product for retinal diseases

Advancement in TED treatment is a bright spot
June 30th 2021

Advancement in TED treatment is a bright spot

Comparable conscious sedation methods address individual patient needs
April 14th 2021

Comparable conscious sedation methods address individual patient needs

Investigators uncover health care disparities among US patients
April 2nd 2021

Investigators uncover health care disparities among US patients

Investigators zoom in on future of dry eye treatment
March 2nd 2021

Investigators zoom in on future of dry eye treatment

Analyzing opioid prescription patterns of US retina specialists
November 16th 2020

Analyzing opioid prescription patterns of US retina specialists

© 2025 MJH Life Sciences

All rights reserved.